The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.
 
Nicholas James Short
No Relationships to Disclose
 
Hagop M. Kantarjian
No Relationships to Disclose
 
Farhad Ravandi
No Relationships to Disclose
 
Naval Guastad Daver
No Relationships to Disclose
 
Naveen Pemmaraju
No Relationships to Disclose
 
Deborah A. Thomas
No Relationships to Disclose
 
Musa Yilmaz
No Relationships to Disclose
 
Tapan M. Kadia
No Relationships to Disclose
 
Koji Sasaki
No Relationships to Disclose
 
Rebecca Garris
No Relationships to Disclose
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
Courtney Denton Dinardo
Honoraria - Agios; Daiichi Sankyo; Novartis
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - AbbVie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
 
Zeev Estrov
No Relationships to Disclose
 
Nitin Jain
No Relationships to Disclose
 
William G. Wierda
Consulting or Advisory Role - Abbvie; Celgene; Emergent BioSolutions; Genentech/Roche; Genzyme; Gilead Sciences; GlaxoSmithKline/Novartis; Merck; Pharmacyclics; Sanofi
Research Funding - Abbvie; Acerta Pharma; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics
 
Vicky Jeanis
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst)
 
Susan Mary O'Brien
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Pfizer; Pharmacyclics; ProNAi; Regeneron; Sunesis Pharmaceuticals; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Amgen Astellas BioPharma; Aptose Biosciences; Celgene; CLL Global Research Foundation; GlaxoSmithKline; Janssen Oncology; Sunesis Pharmaceuticals; Vaniam Group
Research Funding - Acerta Pharma; Gilead Sciences; Pfizer; Pharmacyclics; ProNAI; Regeneron; TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer